Adoptive T cell therapy for solid tumors: current landscape and future challenges.

Autor:	Albarrán V; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., San Román M; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Pozas J; Department of Medical Oncology, The Royal Marsden Hospital, London, United Kingdom., Chamorro J; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Rosero DI; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Guerrero P; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Calvo JC; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., González C; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., García de Quevedo C; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Pérez de Aguado P; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Moreno J; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Cortés A; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Soria A; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Mar 14; Vol. 15, pp. 1352805. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1352805
Abstrakt:	Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate the antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) gene-modified T cells, and therapy with tumor-infiltrating lymphocytes (TILs). The outstanding results of CAR-T cells in some hematologic malignancies have launched the investigation of ACT in patients with refractory solid malignancies. However, certain characteristics of solid tumors, such as their antigenic heterogeneity and immunosuppressive microenvironment, hamper the efficacy of antigen-targeted treatments. Other ACT modalities, such as TIL therapy, have emerged as promising new strategies. TIL therapy has shown safety and promising activity in certain immunogenic cancers, mainly advanced melanoma, with an exciting rationale for its combination with immune checkpoint inhibitors. However, the implementation of TIL therapy in clinical practice is hindered by several biological, logistic, and economic challenges. In this review, we aim to summarize the current knowledge, available clinical results, and potential areas of future research regarding the use of T cell therapy in patients with solid tumors. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Albarrán, San Román, Pozas, Chamorro, Rosero, Guerrero, Calvo, González, García de Quevedo, Pérez de Aguado, Moreno, Cortés and Soria.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu